[go: up one dir, main page]

WO2023186065A1 - Inhibiteur de kinase dependante de la cycline - Google Patents

Inhibiteur de kinase dependante de la cycline Download PDF

Info

Publication number
WO2023186065A1
WO2023186065A1 PCT/CN2023/085372 CN2023085372W WO2023186065A1 WO 2023186065 A1 WO2023186065 A1 WO 2023186065A1 CN 2023085372 W CN2023085372 W CN 2023085372W WO 2023186065 A1 WO2023186065 A1 WO 2023186065A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
ring
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/085372
Other languages
English (en)
Inventor
Lei MO
Junkai Huang
Kai Li
Xiaohui Hu
Li Zhou
Tao CUI
Dongqiang CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taizhou Eoc Pharma Co Ltd
Original Assignee
Taizhou Eoc Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taizhou Eoc Pharma Co Ltd filed Critical Taizhou Eoc Pharma Co Ltd
Publication of WO2023186065A1 publication Critical patent/WO2023186065A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present disclosure provides a compound having the structure of formula (I) ,
  • A is optionally substituted ring
  • B is optionally substituted ring
  • each R 1 , R 2 , R 3 , R 4 , and R 5 is independently absent or is independently selected from optional substituents,
  • A is optionally substituted heterocycle
  • B is optionally substituted ring with one or more ortho-position substituent group
  • each R 1 , R 2 and R 3 is independently absent or is independently selected from optional substituents.
  • the present disclosure provides a compound having the structure of formula (III) ,
  • X 1 is independently selected from optionally substituted atom
  • each R 1 , R 2 , R 3 and R 4 is independently absent or is independently selected from optional substituents, n is 0 or more.
  • substituents may include e.g., methyl, ethyl, propyl (including n-propyl and isopropyl) , butyl (including n-butyl, isobutyl, sec-butyl and terf-butyl) , pentyl, isoamyl, hexyl and the like.
  • the number of carbon atoms in a hydrocarbyl substituent i.e., alkyl, alkenyl, cycloalkyl, aryl, etc.
  • C 1 -C 6 alkyl may refer to an alkyl substituent containing from 1 to 6 carbon atoms.
  • the “alkyl” groups may be optionally substituted with one or more substitutions.
  • alkenyl groups include, but are not limited thereto, ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl.
  • alkenyl contain groups having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations. In some instances, the number of carbon atoms may be indicated by the prefix “C a -C b ” wherein a is the minimum and b is the maximum number of carbon atoms in the substituent.
  • the “alkenyl” groups may be optionally substituted with one or more substitutions.
  • alkynyl generally refers to linear or branched carbon radicals having at least one carbon-carbon triple bond.
  • the term “alkynyl” may contain conjugated and non-conjugated carbon-carbon triple bonds or combinations thereof.
  • Alkynyl group for example and without being limited thereto, may contain two to about twenty carbon atoms or, in a particular embodiment, two to about twelve carbon atoms. In embodiments, alkynyl groups may contain two to about ten carbon atoms. Some examples may be alkynyl having two to about four carbon atoms (such as 2, 3 or more carbon atoms) .
  • the number of carbon atoms may be indicated by the prefix “C a -C b ” wherein a is the minimum and b is the maximum number of carbon atoms in the substituent.
  • Examples of such groups include propargyl, butynyl, and the like.
  • the “alkynyl” groups may be optionally substituted with one or more substitutions.
  • amino As used herein, the term “amino” , either alone or within other terms, generally refers to formula -NH 2 group.
  • the “amino” groups may be optionally substituted with one or more substitutions.
  • ring generally refers to a ring system or a ring structure.
  • ring may comprise carbocycle, heterocycle, aryl, or heteroaryl.
  • ring membered or “membered ring” generally refers to a ring system having ring atoms.
  • n ring membered or “n-membered ring” generally refers to a ring system having n ring atoms.
  • 5 ring membered or “5-membered ring” generally refers to a ring system having 5 ring atoms which optionally contains one or more further heteroatom (s) selected from O, S or N.
  • Bicyclic carbocycles may have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4, 5] , [5, 5] , [5, 6] or [6, 6] system, or 9 or 10 ring atoms arranged as a bicyclo [5, 6] or [6, 6] system.
  • the term “carbocycle” may contain, for example, a monocyclic carbocycle ring fused to an aryl ring (e.g., a monocyclic carbocycle ring fused to a benzene ring) .
  • Carbocyles may have 3 to 8 carbon ring atoms.
  • a monocylic heterocycle may have 3 to 7 ring members (e.g., 2 to 6 carbon atoms and 1 to 3 heteroatoms independently selected from N, O, P, or S)
  • a bicyclic heterocycle may have 5 to 10 ring members (e.g., 4 to 9 carbon atoms and 1 to 3 heteroatoms independently selected from N, O, P, or S)
  • the heterocycle that contains the heteroatom may be non-aromatic. Unless otherwise noted, the heterocycle is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • the number of carbon atoms may be indicated by the prefix “C a -C b ” wherein a is the minimum and b is the maximum number of carbon atoms in the substituent.
  • the “heterocycle” groups may be optionally substituted with one or more substitutions.
  • aryl generally refers to an aromatic substituent containing one ring or two or three fused rings.
  • the aryl substituent may have six to eighteen carbon atoms.
  • the aryl substituent may have six to fourteen carbon atoms.
  • the term “aryl” may refer to substituents such as phenyl, naphthyl and anthracenyl.
  • aryl may also contain substituents such as phenyl, naphthyl and anthracenyl that are fused to a C 4 -C 10 carbocyclic ring, such as a C 5 or a C 6 carbocyclic ring, or to a 4-to 10-membered heterocyclic ring, wherein a group having such a fused aryl group as a substituent is bound to an aromatic carbon of the aryl group.
  • substituents such as phenyl, naphthyl and anthracenyl that are fused to a C 4 -C 10 carbocyclic ring, such as a C 5 or a C 6 carbocyclic ring, or to a 4-to 10-membered heterocyclic ring, wherein a group having such a fused aryl group as a substituent is bound to an aromatic carbon of the aryl group.
  • the one or more substituents may be each bound to an aromatic carbon of the fused aryl group.
  • the number of carbon atoms may be indicated by the prefix “C a -C b ” wherein a is the minimum and b is the maximum number of carbon atoms in the substituent.
  • the “aryl” groups may be optionally substituted with one or more substitutions.
  • heteroaryl generally refers to an aromatic ring structure containing from 5 to 14 ring atoms in which at least one of the ring atoms is a heteroatom (for example, oxygen, nitrogen, or sulfur) , with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
  • a heteroaryl may be a single ring or 2 or 3 fused rings.
  • heteroaryl substituents may include but not limited to: 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, and pyridazinyl; 5-membered ring substituents such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1, 2, 3-, 1, 2, 4-, 1, 2, 5-, or 1, 3, 4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, isobenzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl; and 6/6-membered fused ring substituents such as quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and 1, 4-
  • the group or substituent may be bound to the at least one heteroatom, or it may be bound to a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom.
  • the number of carbon atoms may be indicated by the prefix “C a -C b ” wherein a is the minimum and b is the maximum number of carbon atoms in the substituent.
  • the “heteroaryl” groups may be optionally substituted with one or more substitutions.
  • halogen generally refers to fluorine (which may be depicted as -F) , chlorine (which may be depicted as -Cl) , bromine (which may be depicted as -Br) , or iodine (which may be depicted as -I) .
  • the halogen may be chlorine.
  • the halogen may be fluorine.
  • the halogen may be bromine.
  • cyano As used herein, the term “cyano” , either alone or within other terms, generally refers to formula -CN group.
  • hydroxy generally refers to formula -OH group.
  • the “hydroxy” groups may be optionally substituted with one or more substitutions.
  • the term “phosphorous-containing group” generally refers to functional group containing on or more phosphorous atoms.
  • silicon-containing group generally refers to functional group containing on or more silicon atoms.
  • the silicon -containing group may refer to -SiH 3 .
  • the “silicon-containing group” may be optionally substituted with one or more substitutions.
  • the “carboxyl” groups may be optionally substituted with one or more substitutions.
  • the “sulfonyl” groups may be optionally substituted with one or more substitutions.
  • the “sulfinyl” groups may be optionally substituted with one or more substitutions.
  • acyl generally refers to a carboxylic acid ester of the formula -C (O) R in which the non-carbonyl moiety of the ester group (i.e., R) may be selected from straight, branched, or cyclic alkyl.
  • the term acyl may include but not limited to acetyl, propionyl, butyryl and pentanoyl.
  • the number of carbon atoms may be indicated by the prefix “C a -C b ” wherein a is the minimum and b is the maximum number of carbon atoms in the substituent.
  • the “acyl” groups may be optionally substituted with one or more substitutions.
  • the term “pharmaceutically acceptable salt” generally refers to a salt that may be pharmaceutically acceptable and that may possess the desired pharmacological activity of the parent compound.
  • Such salts may include: acid addition salts, formed with inorganic acids or formed with organic acids or basic addition salts formed with the conjugate bases of any of the inorganic acids wherein the conjugate bases comprise a cationic component.
  • Proper fluidity may be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
  • These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
  • Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
  • Injectable depot forms may be made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly (orthoesters) and poly (anhydrides) . Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release may be controlled. Depot injectable formulations may be also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers may include sugars such as lactose. Desirably, at least 95%by weight of the particles of the active ingredient may have an effective particle size in the range of 0.01 to 10 micrometers.
  • prodrug generally refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention.
  • Typical examples of prodrugs may include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
  • Prodrugs may include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, dedcylated, phosphorylated, dephosphorylated to produce the active compound.
  • cyclin-dependent kinase generally refers to a protein having an activity of regulating the cell cycle.
  • inhibiting cyclin-dependent kinase (CDK) activity may comprise interacting with a cyclin-CDK complex to block kinase activity.
  • CDK may comprise CDK7.
  • the UniProt ID for CDK7 may be P50613.
  • a substituent is “substitutable” or can be “substituted” if it comprises at least one atom that is bonded to one or more hydrogen atoms. If a substituent is described as being “substituted, ” hydrogen or a non-hydrogen substituent is in the place of a hydrogen substituent on a atom of the substituent.
  • a substituted alkyl substituent is an alkyl substituent wherein at least one hydrogen or a non-hydrogen substituent is in the place of a hydrogen substituent on the alkyl substituent.
  • monofluoroalkyl is alkyl substituted with a fluoro substituent
  • difluoroalkyl is alkyl substituted with two fluoro substituents. It should be recognized that if there is more than one substitution on a substituent, each substituent may be identical or different (unless otherwise stated) .
  • optionally substituted or “optional substituent (s) ” generally refers to a given moiety may consist of only hydrogen substituents through available valencies (unsubstituted) or may further comprise one or more non-hydrogen substituents through available valencies (substituted) that are not otherwise specified by the name of the given moiety.
  • a non-hydrogen substituent may be any substituent that may be bound to an atom of the given moiety that is specified to be substituted.
  • the term “formula” may be hereinafter referred to as a “compound (s) of the invention” . Such terms are also defined to include all forms of the compound of formula, including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, and metabolites thereof.
  • the compounds of formula, or pharmaceutically acceptable salts thereof may exist in unsolvated and solvated forms.
  • the complex When the solvent or water is tightly bound, the complex may have a well-defined stoichiometry independent of humidity.
  • the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content may be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
  • the compounds of “formula” may have asymmetric carbon atoms.
  • the carbon-carbon bonds of the compounds of formula may be depicted herein using a solid line, a solid wedge, or a dotted wedge.
  • the use of a solid line to depict bonds to asymmetric carbon atoms may be meant to indicate that all possible stereoisomers (e.g. specific enantiomers, racemic mixtures, etc. ) at that carbon atom are included.
  • the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms may be meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the present application may contain more than one asymmetric carbon atom.
  • a solid line to depict bonds to asymmetric carbon atoms may be meant to indicate that all possible stereoisomers are meant to be included.
  • the compounds of formula can exist as enantiomers and diastereomers or as racemates and mixtures thereof.
  • the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of formula and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound may be meant to indicate that a mixture of diastereomers is present.
  • the compounds of the present application may exist as clathrates or other complexes. Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host may be present in stoichiometric or non-stoichiometric amounts. Also included may be complexes of formula containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized.
  • Stereoisomers of formula may include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers, conformational isomers, and tautomers of the compounds of formula, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs) . Also included may be acid addition or base addition salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.
  • the first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts.
  • the second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
  • the compounds of formula may exhibit the phenomena of tautomerism and structural isomerism.
  • the compounds of formula may exist in several tautomeric forms, including the enol and imine forms, and the keto and enamine forms, and geometric isomers and mixtures thereof. All such tautomeric forms may be included within the scope of compounds of formula.
  • Tautomers may exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer predominates. Even though one tautomer may be described, the present invention includes all tautomers of the compounds of formula.
  • the present invention also includes isotopically-labeled compounds, which are identical to those recited in formula above, but for the fact that one or more atoms may be replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that may be incorporated into compounds of formula include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl.
  • isotopically-labeled compounds of formula for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, may be useful in drug and/or substrate tissue distribution assays.
  • Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes may be particularly used for their ease of preparation and detectability.
  • substitution with heavier isotopes such as deuterium, i.e., 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be used in some circumstances.
  • Isotopically-labeled compounds of formula may generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.
  • the compounds of the present application may be used in the form of salts derived from inorganic or organic acids.
  • a salt of the compound may be advantageous due to one or more of the salt's physical properties, such as enhanced pharmaceutical stability in differing temperatures and humidity, or a desirable solubility in water or oil.
  • a salt of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
  • the present application provides a compound having the structure of formula (I) ,
  • A is optionally substituted ring
  • B is optionally substituted ring
  • each R 1 , R 2 , R 3 , R 4 , and R 5 is independently absent or is independently selected from optional substituents,
  • each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 and X 10 is independently absent or is independently selected from optionally substituted atom, wherein, m is 0 or more, and n is 0 or more.
  • R 1 is H.
  • R 2 is H.
  • R 3 is H.
  • said A is optionally substituted heteroaryl or optionally substituted heterocycle.
  • said A is optionally substituted ring containing one or more N, one or more S and/or one or more O.
  • said A is optionally substituted ring containing one, two or three N.
  • said A is optionally substituted ring containing one O.
  • said A is optionally substituted ring containing one S.
  • said A is selected from the group consisting of optionally substituted pyrrolyl, optionally substitutedpiperidinyl, optionally substitutedpyridinyl, optionally substitutedpiperazinyl, optionally substitutedpiperidinyl , optionally substitutedpyrrolidinyl, optionally substitutedthiazolyl, optionally substituteddiazaspiro [5.5] undecanyl, optionally substitutedpyrazolyl, optionally substitutedazaspiro [5.5] undecanyl, and optionally substitutedimidazolyl.
  • said R 4 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted hydroxyl, and optionally substituted ring.
  • said R 4 is selected from the group consisting of optionally substituted methyl, optionally substituted ethyl, and optionally substituted propyl.
  • said R 4 is optionally substituted 4-ring-membered ring, 5-ring-membered ring or optionally substituted 6-ring-membered ring.
  • said R 4 is optionally substituted ring containing one or more N.
  • said R 4 is optionally substituted ring containing one or two N.
  • said R 4 is optionally substituted azetidinyl.
  • each said R 4-1 is independently absent or is independently selected from optional substituents.
  • said R 4 is substituted with one or two said R 4-1 .
  • each said R 4-1 is independently selected from the group consisting of hydrogen, halogen, and optionally substituted hydroxyl.
  • each said R 4-1 is independently selected from the group consisting of hydrogen, optionally substituted hydroxyl, optionally substituted amino, and optionally substituted methyl.
  • each said R 4-2 is independently absent or is independently selected from optional substituents.
  • said R 4-1 is substituted with one said R 4-2 .
  • each said R 4-2 is independently selected from the group consisting of hydrogen, and halogen.
  • each said R 4-2 is independently selected from the group consisting of hydrogen, and F.
  • said B is optionally substituted 4-ring-membered ring or 6-ring-membered ring.
  • said B is optionally substituted ring containing one or more N and/or one or more O.
  • said B is optionally substituted ring containing one, or two N.
  • said B is optionally substituted ring containing one O.
  • said B is selected from the group consisting of optionally substituted piperidinyl, optionally substituted piperazinyl, and optionally substituted azetidinyl.
  • n 1
  • each said R 5 is independently selected from the group consisting of hydrogen, optionally substituted hydroxyl, optionally substituted amino, and optionally substituted alkyl.
  • each said R 5 is independently selected from the group consisting of hydrogen, optionally substituted hydroxyl, optionally substituted amino, optionally substituted methyl, optionally substituted ethyl, optionally substituted propyl and optionally substituted butyl.
  • each said R 5-1 is independently absent or is independently selected from optional substituents.
  • said R 5 is substituted with one said R 5-1 .
  • each said R 5-1 is independently selected from the group consisting of hydrogen, optionally substituted hydroxyl, and optionally substituted alkyl.
  • each said R 5-1 is independently selected from the group consisting of optionally substituted hydroxyl, optionally substituted methyl, optionally substituted ethyl, and optionally substituted propyl.
  • each said R x7-1 is independently absent or is independently selected from optional substituents.
  • said X 7 is substituted with one said R x7-1 .
  • said R x7-1 is optionally substituted alkyl or optionally substituted ring.
  • said R x7-1 is selected from the group consisting of optionally substituted methyl, optionally substituted ethyl, optionally substituted propyl, optionally substituted butyl, optionally substituted cyclopropyl, and optionally substituted cyclopentyl.
  • said X 9 is substituted with one or more said B.
  • the present application provides a compound or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, or a solvate or hydrate of any of the foregoing, wherein, said compound is selected from the group consisting of:
  • the present application provides a compound having the structure of formula (II) ,
  • A is optionally substituted heterocycle
  • B is optionally substituted ring with one or more ortho-position substituent group
  • each X 1 and X 2 is independently absent or is independently selected from optionally substituted atom
  • each R 1 , R 2 and R 3 is independently absent or is independently selected from optional substituents.
  • said A is optionally substituted 6-ring-membered ring.
  • said A is optionally substituted heterocycle.
  • said A is optionally substituted ring containing one or more N.
  • said A is optionally substituted ring containing one, two or three N.
  • R A-1 is selected from the group consisting of hydrogen, and optionally substituted amino.
  • said B is optionally substituted 5 or 6-ring-membered ring.
  • said B is optionally substituted aryl or optionally substituted heteroaryl.
  • said B is optionally substituted ring containing no N or one or more N.
  • said B is selected from the group consisting of optionally substituted phenyl and optionally substituted pyridinyl.
  • each said R B-1 is independently absent or is independently selected from optional substituents.
  • R B-1 is on the ortho-position of said B.
  • R B-1 is optionally substituted heterocycle or optionally substituted heteroaryl.
  • said R B-1 is optionally substituted ring containing one or more N.
  • R B-1 is optionally substituted ring containing one, or two N.
  • said R B-1 is selected from the group consisting of optionally substituted pyrazolyl, optionally substituted pyridinyl, and optionally substituted piperazinyl.
  • each said R B-2 is independently absent or is independently selected from optional substituents .
  • each said R B-2 is independently selected from the group consisting of hydrogen, optionally substituted amino, optionally substituted alkyl, and optionally substituted heterocycle.
  • said R B-2 is independently selected from the group consisting of hydrogen, optionally substituted amino, optionally substituted methyl, and optionally substituted piperazinyl.
  • each said R B-3 is independently absent or is independently selected from optional substituents.
  • R B-3 is optionally substituted alkyl.
  • R B-3 is optionally substituted methyl.
  • R X1-1 is selected from the group consisting of hydrogen, and optionally substituted alkyl.
  • R X1-1 is optionally substituted propyl.
  • R X1-1 is optionally substituted isopropyl.
  • R 1 is H.
  • R 2 is H.
  • R 3 is H.
  • the present application provides a compound or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, or a solvate or hydrate of any of the foregoing, wherein, said compound is selected from the group consisting of:
  • the present application provides a compound having the structure of formula (III) ,
  • X 1 is independently selected from optionally substituted atom
  • each R 1 , R 2 , R 3 and R 4 is independently absent or is independently selected from optional substituents
  • n is 0 or more.
  • said R 1 is selected from the group consisting of halogen, CN, optionally substituted alkyl, optionally substituted acyl, optionally substituted amino, optionally substituted hydroxyl, optionally substituted phosphorous-containing group, optionally substituted sulfonyl, and optionally substituted ring.
  • said R 1 is selected from the group consisting of optionally substituted alkyl, optionally substituted amino, optionally substituted hydroxyl, and optionally substituted ring.
  • said R 1 is selected from the group consisting of optionally substituted methyl, and optionally substituted ethyl.
  • said R 1 is selected from the group consisting of optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl.
  • said R 1 is optionally substituted 6-ring-membered ring.
  • said R 1 is optionally substituted cyclohexanyl.
  • said R 1 is optionally substituted 6 to 8-ring-membered ring.
  • said R 1 is optionally substituted ring containing one or more N and/or one or more O.
  • said R 1 is optionally substituted ring containing one, two or three N and/or one, two or three O.
  • said R 1 is optionally substituted ring containing one or two N.
  • said R 1 is optionally substituted piperazinyl, optionally substituted piperidinyl, or optionally substituted diazepanyl.
  • said R 1 is optionally substituted bicyclic ring.
  • said R 1 is optionally substituted diazabicycloheptanyl, or optionally substituted diazabicyclooctanyl.
  • said R 1 is optionally substituted benzenyl.
  • said R 1 is optionally substituted 5 to 12-ring-membered ring.
  • said R 1 is optionally substituted ring containing one or more N and/or one or more O.
  • said R 1 is optionally substituted ring containing one, two or three N and/or one, two or three O.
  • said R 1 is optionally substituted ring containing one, two or five N.
  • said R 1 is optionally substituted ring containing one O.
  • said R 1 is optionally substituted pyrrolyl, optionally substituted oxazolyl, optionally substituted pyrazolyl, optionally substituted oxadiazolyl, optionally substituted pyridinyl, or optionally substituted pyrazinyl.
  • said R 1 is optionally substituted fused ring.
  • said R 1 is optionally substituted pyrazolopyridinyl or optionally substituted quinolinyl.
  • each said R 1-1 is independently absent or is independently selected from optional substituents.
  • said R 1 is substituted with one, two or three R 1-1 .
  • said R 1 is substituted with one or two said R 1-1 .
  • each said R 1-1 is independently selected from the group consisting of optionally substituted methyl, optionally substituted ethyl and optionally substituted propyl.
  • each said R 1-1 is independently selected from the group consisting of optionally substituted methyl, optionally substituted ethyl and optionally substituted isopropyl.
  • each said R 1-1 is independently selected from the group consisting of optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl.
  • said R 1-1 is optionally substituted 4 to 5-ring-membered ring.
  • said R 1-1 is optionally substituted ring containing one or more N and/or one or more O.
  • said R 1-1 is optionally substituted ring containing one, two or three N and/or one, two or three O.
  • said R 1-1 is optionally substituted ring containing one N.
  • said R 1-1 is optionally substituted azetidinyl, or optionally substituted pyrrolidinyl.
  • said R 1-1 is optionally substituted benzenyl.
  • said R 1-1 is optionally substituted 6-ring-membered ring.
  • said R 1-1 is optionally substituted ring containing one or more N and/or one or more O.
  • said R 1-1 is optionally substituted ring containing one, two or three N and/or one, two or three O.
  • said R 1-1 is optionally substituted ring containing one N.
  • said R 1-1 is optionally substituted pyridinyl.
  • each said R 1-1 is independently substituted with one or more R 1-2 , each said R 1-2 is independently absent or is independently selected from optional substituents.
  • each said R 1-1 is independently substituted with one, two or three R 1-2 .
  • each said R 1-1 is independently substituted with one, two or three said R 1-2 .
  • each said R 1-2 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted amino, optionally substituted hydroxyl, and optionally substituted ring.
  • each said R 1-2 is F.
  • each said R 1-2 is independently selected from the group consisting of optionally substituted methyl, and optionally substituted ethyl.
  • each said R 1-2 is independently selected from the group consisting of optionally substituted carbocycle, and optionally substituted heteroaryl.
  • said R 1-2 is optionally substituted 5-ring-membered ring.
  • said R 1-2 is optionally substituted cyclopropyl.
  • said R 1-2 is optionally substituted 5-ring-membered ring.
  • said R 1-2 is optionally substituted ring containing one or more N and/or one or more O.
  • said R 1-2 is optionally substituted ring containing one, two or three N and/or one, two or three O.
  • said R 1-2 is optionally substituted ring containing one N.
  • said R 1-2 is optionally substituted furanyl.
  • each said R 1-2 is independently substituted with one or more R 1-3 , each said R 1-3 is independently absent or is independently selected from optional substituents.
  • each said R 1-2 is independently substituted with one, two or three R 1-3 .
  • each said R 1-2 is independently substituted with one, two or three said R 1-3 .
  • each said R 1-3 is independently selected from the group consisting of hydrogen, optionally substituted methyl, and optionally substituted hydroxyl.
  • said R 2 is selected from the group consisting of hydrogen, halogen, CN, optionally substituted alkyl, optionally substituted acyl, optionally substituted amino, optionally substituted hydroxyl, optionally substituted phosphorous-containing group, optionally substituted sulfonyl, and optionally substituted ring.
  • said R 2 is optionally substituted carbocycle.
  • said R 2 is optionally substituted 6-ring-membered ring.
  • said R 2 is optionally substituted ring containing one or more N and/or one or more O.
  • said R 2 is optionally substituted ring containing one, two or three N and/or one, two or three O.
  • said R 2 is optionally substituted ring containing one N.
  • R 2 is optionally substituted piperidinyl.
  • each said R 2-1 is independently absent or is independently selected from optional substituents.
  • said R 2 is substituted with one, two or three R 2-1 .
  • said R 2 is substituted with one said R 2-1 .
  • R 2-1 is optionally substituted amino.
  • said R 3 is selected from the group consisting of hydrogen, halogen, CN, optionally substituted alkyl, optionally substituted acyl, optionally substituted amino, optionally substituted hydroxyl, optionally substituted phosphorous-containing group, optionally substituted sulfonyl, and optionally substituted ring.
  • R 3 is optionally substituted propyl.
  • R 3 is optionally substituted isopropyl.
  • said R 4 is selected from the group consisting of hydrogen, halogen, CN, optionally substituted alkyl, optionally substituted acyl, optionally substituted amino, optionally substituted hydroxyl, optionally substituted phosphorous-containing group, optionally substituted sulfonyl, and optionally substituted ring.
  • R 4 is hydrogen
  • said R 1 is optionally substituted heterocycle.
  • said R 1 is optionally substituted 6-ring-membered heterocycle.
  • said R 1 is optionally substituted 6-ring-membered heterocycle containing one or two N.
  • said R 1 is optionally substituted heteroaryl.
  • said R 1 is optionally substituted 5-ring-membered heteroaryl.
  • said R 1 is optionally substituted 5-ring-membered heteroaryl containing two N.
  • said R 1 is optionally substituted 6-ring-membered heteroaryl.
  • said R 1 is optionally substituted 6-ring-membered heteroaryl containing two N.
  • R 1 is substituted with one or more R 1-1 , each said R 1-1 is independently absent or is independently selected from optional substituents.
  • each said R 1-1 is optionally substituted methyl or two methyl substituted amino.
  • the present application provides a compound or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, or a solvate or hydrate of any of the foregoing, wherein, said compound is selected from the group consisting of:
  • the present application provides a method for inhibiting cyclin-dependent kinase (CDK) activity, said method comprising administering to a subject in need thereof an effective amount of the present application, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, or a solvate or hydrate of any of the foregoing.
  • said cyclin-dependent kinase (CDK) may be CDK 7.
  • said method may be selected from the group consisting of an in vitro method, an ex vivo method, and an in vivo method.
  • the present application provides use the compound of the present application, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, or a solvate or hydrate of any of the foregoing of the present application in the preparation of a drug and/or a kit for use in inhibiting cyclin-dependent kinase (CDK) activity.
  • said cyclin-dependent kinase (CDK) may be CDK 7.
  • said method of using said drug and/or said kit may be selected from the group consisting of an in vitro method, an ex vivo method, and an in vivo method.
  • the present application provides the compound of the present application, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, or a solvate or hydrate of any of the foregoing of the present application for use in inhibiting cyclin-dependent kinase (CDK) activity.
  • said cyclin-dependent kinase (CDK) may be CDK 7.
  • said method or said use may be selected from the group consisting of an in vitro method, an ex vivo method, and an in vivo method.
  • the present application provides a composition comprising a compound of the present application, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, or a solvate or hydrate of any of the foregoing, and optionally a pharmaceutically acceptable carrier.
  • the compounds of the application may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • the compounds of the present application may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration may include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration may include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • the compounds of the present application may also be administered topically to the skin or mucosa, that is, dermally or transdermally. In some cases, the compounds of the present application may also be administered intranasally or by inhalation. In some cases, the compounds of the present application may be administered rectally or vaginally. In another embodiment, the compounds of the present application may also be administered directly to the eye or ear.
  • the dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus, the dosage regimen may vary widely. Dosage levels of body weight per day may be useful.
  • Suitable subjects according to the present invention include mammalian subjects. Mammals according to the present invention may include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In one embodiment, humans are suitable subjects. Human subjects may be of either gender and at any stage of development.
  • the present application provides use of one or more compounds of the present application for the preparation of a medicament.
  • the compounds of the present application may be administered as compound per se.
  • pharmaceutically acceptable salts may be suitable for medical applications because of their greater aqueous solubility relative to the parent compound.
  • compositions may comprise a compound of the present application presented with a pharmaceutically acceptable carrier.
  • the carrier may be a solid product, a liquid, or both, and may be formulated with the compound as a unit-dose composition, for example, a tablet, which may contain the active compounds.
  • a compound of the present application may be coupled with suitable polymers as targetable drug carriers. Other pharmacologically active substances may also be present.
  • the compounds of the present invention may be administered by any suitable route, maybe in the form of a pharmaceutical composition adapted to such a route.
  • the active compounds and compositions may be administered orally, rectally, parenterally, or topically.
  • the compounds of the present application may be used, alone or in combination with other therapeutic agents.
  • the compound (s) of the present application and other therapeutic agent (s) may be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially.
  • the administration of two or more compounds “in combination” may mean that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other.
  • the two or more compounds may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
  • Standard abbreviations may be used, e.g., bp, base pair (s) ; kb, kilobase (s) ; pl, picoliter (s) ; s or sec, second (s) ; min, minute (s) ; h or hr, hour (s) ; aa, amino acid (s) ; nt, nucleotide (s) ; i. m., intramuscular (ly) ; i.p., intraperitoneal (ly) ; s.c., subcutaneous (ly) ; and the like.
  • the crude product was purified by Prep-HPLC with the following conditions: Column: XBridge Prep OBD C 18 Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 ⁇ H 2 O) , Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 43%B to 63%B in 7 min; Wave Length: 254 nm to afford 2- (4-aminopiperidin-1-yl) -9-isopropyl- N- ( ⁇ 2- [3- (prop-1-en-2-yl) pyrrol-1-yl] phenyl ⁇ methyl) purin-6-amine (12.6 mg, 11%yield) as a white solid.
  • the crude product was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 ) , Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 30%B to 45%B in 10 min; Wave Length: 254 nm to afford 2- (4-aminopiperidin-1-yl) -N- ⁇ [6'- (difluoromethoxy) - [2, 3'-bipyridin] -3-yl] methyl ⁇ -9-isopropylpurin-6-amine (59.7 mg, 52%yield) as a white solid.
  • the product obtained is a thick oil (2- (3- (3, 3-difluoropyrrolidin-1-yl) -1H-pyrazol-1-yl) phenyl) methanamine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une série de composés utilisés en tant qu'inhibiteurs puissants de la kinase dépendante de la cycline (CDK), ou des sels pharmaceutiquement acceptables de ceux-ci. L'invention concerne également des compositions correspondantes.
PCT/CN2023/085372 2022-04-02 2023-03-31 Inhibiteur de kinase dependante de la cycline Ceased WO2023186065A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2022085014 2022-04-02
CNPCT/CN2022/085014 2022-04-02
CNPCT/CN2022/122533 2022-09-29
CN2022122533 2022-09-29

Publications (1)

Publication Number Publication Date
WO2023186065A1 true WO2023186065A1 (fr) 2023-10-05

Family

ID=88199428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/085372 Ceased WO2023186065A1 (fr) 2022-04-02 2023-03-31 Inhibiteur de kinase dependante de la cycline

Country Status (1)

Country Link
WO (1) WO2023186065A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025040170A1 (fr) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 Nouveau composé hétérocyclique condensé servant d'inhibiteur de cdk et son utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036380A1 (fr) * 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
WO2016160617A2 (fr) * 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
WO2022206795A1 (fr) * 2021-04-02 2022-10-06 Taizhou Eoc Pharma Co., Ltd. Inhibiteur de kinase dépendante de la cycline
WO2023016477A1 (fr) * 2021-08-11 2023-02-16 Taizhou Eoc Pharma Co., Ltd. Inhibiteur de kinases cycline-dépendantes
WO2023046128A1 (fr) * 2021-09-27 2023-03-30 Taizhou Eoc Pharma Co., Ltd. Inhibiteur de kinase dépendante des cyclines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036380A1 (fr) * 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
WO2016160617A2 (fr) * 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
WO2022206795A1 (fr) * 2021-04-02 2022-10-06 Taizhou Eoc Pharma Co., Ltd. Inhibiteur de kinase dépendante de la cycline
WO2023016477A1 (fr) * 2021-08-11 2023-02-16 Taizhou Eoc Pharma Co., Ltd. Inhibiteur de kinases cycline-dépendantes
WO2023046128A1 (fr) * 2021-09-27 2023-03-30 Taizhou Eoc Pharma Co., Ltd. Inhibiteur de kinase dépendante des cyclines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry CAS; 23 April 2021 (2021-04-23), ANONYMOUS : "Thieno[2,3-d]pyrimidin-4 -amine, N-[[2-(1H-imi dazol-2-yl)phenyl]m ethyl]-2- (2-pyridinyl)- ", XP093094687, retrieved from STN Database accession no. 2637184-74-6 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025040170A1 (fr) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 Nouveau composé hétérocyclique condensé servant d'inhibiteur de cdk et son utilisation

Similar Documents

Publication Publication Date Title
ES2953512T3 (es) Compuestos de arilo o heteroarilo sustituidos con amina como inhibidores de EHMT1 y EHMT2
ES2955132T3 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos
ES2400619T3 (es) Inhibidores de imidazopiridina quinasa
ES2751741T3 (es) Procedimiento para fabricar compuestos útiles como inhibidores de la quinasa ATR
AU2016228660B2 (en) Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
WO2024032704A1 (fr) Composés hétérocycliques, compositions à base de ceux-ci et procédés de traitement associés
US12435079B2 (en) Bruton's tyrosine kinase inhibitors
US9150577B2 (en) Heterocyclic compounds containing an indole core
RS59522B1 (sr) Naftiridinska jedinjenja kao inhibitori jak kinaze
TW202102509A (zh) 靶向prmt5之化合物
AU2014400628A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
CN110621675A (zh) 用于治疗增殖性疾病的三环化合物
EP3768272B1 (fr) Inhibiteurs de jak
AU2014298017A1 (en) Heterobicycloaryl RORc2 inhibitors and methods of use thereof
ES3036245T3 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
EA029269B1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
WO2021018118A1 (fr) Composés et procédés pour la dégradation ciblée de protéines de kinase 1 associés au récepteur de l'interleukine 1
CA3141424A1 (fr) Compose cyclique fusionne en tant qu'inhibiteur double de fgfr et vegfr
WO2023046128A1 (fr) Inhibiteur de kinase dépendante des cyclines
WO2023186065A1 (fr) Inhibiteur de kinase dependante de la cycline
KR102833011B1 (ko) 푸로[3,4-b]피롤-함유 BTK 억제제
WO2023040998A1 (fr) Inhibiteur de kinase dépendante des cyclines
KR102682398B1 (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2023016477A1 (fr) Inhibiteur de kinases cycline-dépendantes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23778430

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23778430

Country of ref document: EP

Kind code of ref document: A1